One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia

摘要: Abstract This study reports the results of a 12-month, randomized, double-blind, placebo-controlled to investigate efficacy, safety, and tolerability policosanol (5 mg twice daily) in patients with type II hypercholesterolemia. After low-fat, low-cholesterol diet for at least 12 weeks, 74 were randomized receive placebo or mg) tablets months. Tablets taken daily before morning evening meals. Lipid profile safety indicators controlled regularly throughout study. Significant reductions serum total cholesterol low-density lipoprotein (LDL-C) achieved after 2 months therapy. The treatment effect continued during 12-month follow-up. months, had decreased by 17.2% LDL-C 26.4%. Similarly, ratios high-density (HDL-C) HDL-C also significantly reduced group, decreasing 33.3% (LDL-C:HDL-C) 25.3% (cholesterol:HDL-C) In addition, significant, sustained increase 13% 15% occurred policosanol-treated group. No significant changes triglycerides observed compared baseline placebo. Nine discontinued trial (five from group four group), none them because adverse effects. experiences reported mild transient. differences obtained those drug-related clinical biochemical effects detected. It is concluded that administered 5 shows persistent efficacy safe well tolerated